Tocilizumab in systemic sclerosis treatment: a case report

INTRODUCTION: In the United States, tocilizumab was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease because it inhibited the decrease in forced expiratory volume, so scleroderma treatment is entering a new era. CASE PRESENTATION: A 44-year-old female patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudsi, Maysoun, Khalayli, Naram, Tarcha, Raghad, Al-Darwish, Lama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473287/
https://www.ncbi.nlm.nih.gov/pubmed/37663690
http://dx.doi.org/10.1097/MS9.0000000000000969
Descripción
Sumario:INTRODUCTION: In the United States, tocilizumab was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease because it inhibited the decrease in forced expiratory volume, so scleroderma treatment is entering a new era. CASE PRESENTATION: A 44-year-old female patient with systemic scleroderma, diagnosed 6 years ago, presented with breathlessness over the last week. The modified Rodnan’s score was 18. Tocilizumab 162 mg subcutaneously once every 2 weeks was prescribed. After 4 weeks, a decrease in Rodnan score was observed. Tocilizumab was stopped after 6 months without any side effects due to treatment. DISCUSSION: Treatment with tocilizumab may maintain lung function nearly unchanged. Its effect on perfecting skin fibrosis seems promising. Tocilizumab may be fairly safe to use. CONCLUSION: Tocilizumab may be effective and fairly safe to use. Further exploration is anticipated to advance a new period of systemic sclerosis treatment.

Ejemplares similares